Scholar Rock gains after smaller Q2 net loss; FDA review progresses
06/08/2026 17:55
BUZZ-Scholar Rock gains after smaller Q2 net loss; FDA review progresses Updates
** Shares of Scholar Rock SRRK.O rise 6.89% to $51.17
** Q2 net loss per share was 84 cents vs loss of 98 cents per share last year
** Co says FDA review of the application of its spinal muscular atrophy drug continues to advance with two fill-finish facilities, representing two independent paths to a decision by September 30
** We believe the second fill/finish site should support near-term US approval, says brokerage Truist
** Co is prepared for U.S. launch of the drug, apitegromab, immediately upon FDA approval; ample supply available for commercialization
** As of June 30, 2026, SRRK had cash, cash equivalents and marketable securities of $492.1 million
** Stock up 17% YTD
(Reporting by Sriparna Roy in Bengaluru)
Recent news on Scholar Rock Holding
See all newsBrief: Scholar Rock Reports New Employee Inducement Grants
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) To European Medicines Agency (EMA) For Treatment Of Children And Adults With Spinal Muscular Atrophy (SMA)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up